Loading…
Application covers use alone and in combination with GLP-1 receptor agonists.
Artelo Biosciences, Inc. has filed a new provisional patent application for its ART27.13 compound, targeting obesity treatment. The application was prompted by unexpected nonclinical findings, exploring the compound's use both as a standalone treatment and in combination with GLP-1 receptor agonists.
The filing details a new provisional patent application covering ART27.13 for obesity, alone and in combination with GLP-1 receptor agonists.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.